Figure 6. The relationship between high/low molecular prognostic score (mPS) and mutation status shows that wild-type tumors had an approximately equal proportion of high versus low mPS (48% vs 52%), whereas high mPS was less common in tumors with EGFR (35%) or KRAS (30%) mutations (P = 0.002).